2-[3-[(1S)-1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[3-[(1S)-1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
• 化学式: C₃₂H₃₉NO₄
• 分子量: 501.7
• InChiKey: RYHUKJMCYGRCSM-LJAQVGFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  81
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• LIQUID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING FEXOFENADINE
  申请人：Aventisub LLC

  公开号：EP3016635A1

  公开（公告）日：2016-05-11
• [EN] LIQUID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING FEXOFENADINE<br/>[FR] COMPOSITION PHARMACEUTIQUE LIQUIDE POUR UNE ADMINISTRATION ORALE, COMPRENANT DE LA FEXOFÉNADINE
  申请人：AVENTIS PHARMA INC

  公开号：WO2015001478A1

  公开（公告）日：2015-01-08

  The present invention relates to a liquid pharmaceutical composition for oral administration comprising fexofenadine and/or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier which is either polyethylene glycol or a propylene glycol-based solvent, or a mixture thereof, from 35 to 90% wt. of a pharmaceutical excipient stabilizing fexofenadine and/or a pharmaceutically acceptable salt thereof, said pharmaceutical excipient consisting of glycerol with optionally sorbitol. The invention also relates to the uses of these compositions as a medicament and to the process for preparing said compositions.